Extreme elevation of acute phase reactants and shock secondary to dabrafenib-trametinib
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved..
The emerging role of BRAF and MEK tyrosine-kinase inhibitors has shown new opportunities of treatment for patients with advanced melanoma and BRAF mutations. Its use is associated with some toxicities, as pyrexia, that clinicians may not be familiarized with. We present the case of a patient diagnosed with stage IV melanoma BRAF Val600E mutated who was started on dabrafenib and trametinib and developed three severe episodes of fever, hypotension and acute phase reactants elevation during the first 3 months of therapy, in the absence of microbiological demonstration of infection. The episodes were initially managed as a septic shock with broad-spectrum antibiotics and vasoactive drugs, while treatment with dabrafenib and trametinib was withheld. After two subsequent dose reduction of dabrafenib, the patient did not experience new episodes of fever.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Melanoma research - 31(2021), 3 vom: 01. Juni, Seite 268-271 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ayala de Miguel, Pablo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
33E86K87QN |
|---|
| Anmerkungen: |
Date Completed 08.11.2021 Date Revised 01.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/CMR.0000000000000733 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322982502 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322982502 | ||
| 003 | DE-627 | ||
| 005 | 20231225183206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CMR.0000000000000733 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM322982502 | ||
| 035 | |a (NLM)33741812 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ayala de Miguel, Pablo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Extreme elevation of acute phase reactants and shock secondary to dabrafenib-trametinib |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2021 | ||
| 500 | |a Date Revised 01.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a The emerging role of BRAF and MEK tyrosine-kinase inhibitors has shown new opportunities of treatment for patients with advanced melanoma and BRAF mutations. Its use is associated with some toxicities, as pyrexia, that clinicians may not be familiarized with. We present the case of a patient diagnosed with stage IV melanoma BRAF Val600E mutated who was started on dabrafenib and trametinib and developed three severe episodes of fever, hypotension and acute phase reactants elevation during the first 3 months of therapy, in the absence of microbiological demonstration of infection. The episodes were initially managed as a septic shock with broad-spectrum antibiotics and vasoactive drugs, while treatment with dabrafenib and trametinib was withheld. After two subsequent dose reduction of dabrafenib, the patient did not experience new episodes of fever | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Acute-Phase Proteins |2 NLM | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Oximes |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a Pyrimidinones |2 NLM | |
| 650 | 7 | |a trametinib |2 NLM | |
| 650 | 7 | |a 33E86K87QN |2 NLM | |
| 650 | 7 | |a dabrafenib |2 NLM | |
| 650 | 7 | |a QGP4HA4G1B |2 NLM | |
| 700 | 1 | |a Gorospe García, Itziar |e verfasserin |4 aut | |
| 700 | 1 | |a López Gallego, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Borrega García, Pablo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Melanoma research |d 1997 |g 31(2021), 3 vom: 01. Juni, Seite 268-271 |w (DE-627)NLM012645702 |x 1473-5636 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2021 |g number:3 |g day:01 |g month:06 |g pages:268-271 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/CMR.0000000000000733 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2021 |e 3 |b 01 |c 06 |h 268-271 | ||